GCP
ABOS icon

GSA Capital Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

GSA Capital Partners’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,103
Closed -$55K – 1622
2025
Q3 		$55K Hold
32,103
– – ﹤0.01% 1570
2025
Q2 		$37K Buy
+32,103
New +$34.5K ﹤0.01% 1674
2024
Q2 		– Sell
-25,370
Closed -$103K – 1580
2024
Q1 		$103K Buy
+25,370
New +$95.6K 0.01% 1489

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

GSA Capital Partners's ABOS Position: Q4 2025 in Review

GSA Capital Partners sold out of Acumen Pharmaceuticals (ABOS) in Q4 2025, closing a stake of 32,103 shares — an estimated $55K sold.

GSA Capital Partners first reported a position in ABOS in Q1 2024 and held it in 3 quarters. The position peaked at $103K in Q1 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q4 2025.

  • GSA Capital Partners reported no remaining Acumen Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 32,103 Acumen Pharmaceuticals shares in Q4 2025, an estimated $55K.
  • GSA Capital Partners first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • GSA Capital Partners's Acumen Pharmaceuticals position peaked at $103K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.